Literature DB >> 6710425

Atopy, immunological changes, and respiratory function in bronchiectasis.

M B Murphy, D J Reen, M X Fitzgerald.   

Abstract

Cystic fibrosis has been reported to be associated with an increased prevalence of atopy and reversible airways obstruction. To determine whether such features can also result from other chronic suppurative lung infections, we studied 23 patients with proved bronchiectasis, and 23 age and sex matched normal controls. A personal or family history of atopy was reported with equal frequency in the two groups. Although the groups displayed a similar prevalence of positive immediate hypersensitivity skinprick test responses, the positive patients reacted to more antigens (p less than 0.05) and had larger weal diameters (p less than 0.01) than the positive controls. Other indices, such as blood eosinophil counts and serum IgE, did not differ significantly. Serum concentrations of immunoglobulins G, A, and M and of the four IgG subclasses tended to be higher in patients than controls, but only in the case of IgA (p less than 0.01) was this difference significant. No case of IgG subclass deficiency was noted. The patients displayed significant airflow obstruction, the mean basal one second forced expiratory volume (FEV1), forced vital capacity (FVC), and peak expiratory flow rate (PEFR) being 67%, 77%, and 67% of their predicted values. There was evidence of a significant reversible obstructive component in that FEV1 or PEFR or both increased by 15% or more in nine of the 23 patients after inhalation of fenoterol, the mean increases in FEV1, FVC, and PEFR for the whole group being 9.5%, 11%, and 16.9%. These results indicate that while bronchiectasis provokes a hyperimmune response it differs from cystic fibrosis in that there is no significant increase in the prevalence of atopy. The finding of reversible airways obstruction, however, suggests that bronchodilators may be useful adjuncts to treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6710425      PMCID: PMC459758          DOI: 10.1136/thx.39.3.179

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

1.  Standardization of bronchial inhalation challenge procedures.

Authors:  H Chai; R S Farr; L A Froehlich; D A Mathison; J A McLean; R R Rosenthal; A L Sheffer; S L Spector; R G Townley
Journal:  J Allergy Clin Immunol       Date:  1975-10       Impact factor: 10.793

2.  Short-term anaphylactic IgG antibodies in human sera.

Authors:  W E Parish
Journal:  Lancet       Date:  1970-09-19       Impact factor: 79.321

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Factors associated with respiratory insufficiency in bronchiectasis.

Authors:  N S Cherniack; R W Carton
Journal:  Am J Med       Date:  1966-10       Impact factor: 4.965

5.  Prevalence of atopy and exercise-induced bronchial lability in relatives of patients with cystic fibrosis.

Authors:  R Counahan; M B Mearns
Journal:  Arch Dis Child       Date:  1975-06       Impact factor: 3.791

6.  A quantitative study of the distribution of IgG sub-classes in a group of normal human sera.

Authors:  F Shakib; D R Stanworth; R Drew; D Catty
Journal:  J Immunol Methods       Date:  1975       Impact factor: 2.303

7.  Chronic infections in a family with hereditary deficiency of IgG2 and IgG4.

Authors:  V A Oxelius
Journal:  Clin Exp Immunol       Date:  1974-05       Impact factor: 4.330

8.  Quantification of IgG subclasses in sera of normal adults and healthy children between 4 and 12 years of age.

Authors:  M van der Giessen; E Rossouw; T A van Veen; E van Loghem; B J Zegers; P C Sander
Journal:  Clin Exp Immunol       Date:  1975-09       Impact factor: 4.330

9.  Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection.

Authors:  D W Empey; L A Laitinen; L Jacobs; W M Gold; J A Nadel
Journal:  Am Rev Respir Dis       Date:  1976-02

10.  Association of cystic fibrosis with allergy.

Authors:  J O Warner; B W Taylor; A P Norman; J F Soothill
Journal:  Arch Dis Child       Date:  1976-07       Impact factor: 3.791

View more
  15 in total

Review 1.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Nebulisers for bronchiectasis.

Authors:  D C Currie
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

3.  Prevalence of asthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study.

Authors:  J Pang; H S Chan; J Y Sung
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

4.  Chronic bronchial sepsis and progressive lung damage.

Authors:  G M Cochrane
Journal:  Br Med J (Clin Res Ed)       Date:  1985-04-06

5.  Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.

Authors:  Timothy R Aksamit; Anne E O'Donnell; Alan Barker; Kenneth N Olivier; Kevin L Winthrop; M Leigh Anne Daniels; Margaret Johnson; Edward Eden; David Griffith; Michael Knowles; Mark Metersky; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Betsy Carretta; Charles L Daley
Journal:  Chest       Date:  2016-11-23       Impact factor: 9.410

Review 6.  Chronic obstructive pulmonary disease and asthma. General and medical management with special attention to exacerbations.

Authors:  J P Kaajan
Journal:  Pharm Weekbl Sci       Date:  1989-08-25

7.  IgG subclasses in the serum and sputum from patients with bronchiectasis.

Authors:  S L Hill; J L Mitchell; D Burnett; R A Stockley
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

8.  Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis.

Authors:  M Gaga; A M Bentley; M Humbert; J Barkans; F O'Brien; C G Wathen; A B Kay; S R Durham
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

Review 9.  Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?

Authors:  Paul King
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Serum IgG subclasses in chronic and recurrent respiratory infections.

Authors:  P J Stanley; G Corbo; P J Cole
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.